Baker McKenzie assisted MicroPort Cardiac Rhythm Management Limited ("MicroPort® CRM"), a company that conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure, and which is a subsidiary of MicroPort Scientific Corporation ("MicroPort®"), in relation to the conclusion of "type B" financing agreements for a complex investment of USD 105 million.

A well-known Asian fund will drive "type B" financing with an investment of USD 50 million. A current MicroPort® CRM investor will participate with an additional investment of USD 25 million. MicroPort® will invest USD 30 million through its wholly owned subsidiary MicroPort International Corp. Limited ("MicroPort® International"). Following the completion of this transaction, MicroPort® International will continue to be the majority shareholder of MicroPort® CRM.

Baker McKenzie assisted MicroPort® with a team coordinated by Partner Aurelio Giovannelli and Counsel Antonio Lattanzio, in coordination with the in-house legal teams of Shanghai MicroPort Medical (Group) Co. Ltd., composed of Kim Xueqin Wu, Catharine Zhou and Pam Lv, and MicroPort Scientific Corporation (CRM), composed of Carolin Sonja Vanscheidt and Alice Flacco.

Explore Our Newsroom